January 22, 2015

Longer Duration of Dual Antiplatelet Therapy Reduces Some Risks, Increases Others

A closer look at extended antiplatelet therapy

DAPT-690×380

Results of the Dual Antiplatelet Therapy (DAPT) trial presented at the American Heart Association 2014 Scientific Session found that extending therapy from 12 to 30 months after stenting reduced the risks of stent thrombosis and major adverse cardiovascular and cerebrovascular events (MACCE), but at a price.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Current American College of Cardiology/American Heart Association guidelines for stenting recommend dual antiplatelet therapy with clopidogrel or related drugs and aspirin for 12 months in patients who receive drug-eluting stents (DES), after which aspirin monotherapy is continued indefinitely.

The trial evaluated the rate of stent thrombosis and MACCE (a composite of death, myocardial infarction or stroke) in 8,308 patients with DES and 1,718 with bare-metal stents treated with a thienopyridine agent plus aspirin or placebo for an additional 18 months. Longer treatment reduced the rate of stent thrombosis by 1 percent and MACCE by 1.5 percent. The rate of myocardial infarction (MI) was 2 percent lower with thienopyridine than placebo, and the rate of death was 0.5 percent lower.

However, extended use of dual antiplatelet therapy increased the rate of moderate or severe bleeding by 0.9 percent. Additionally, rates of stent thrombosis and MI increased within three months after thienopyridine treatment was discontinued.

Advertisement

“This was an important trial, because it was the first to look at extended length of dual antiplatelet therapy and provided important information on benefits versus risks,” says Steven Nissen, MD, Chairman of Cardiovascular Medicine at Cleveland Clinic. “However, the optimal duration of therapy remains unknown.”

Related Articles

21-HVI-2541213_chest-pain_650x450
December 14, 2021
New Guideline Helps Evaluate Risk in Patients With Chest Pain

Further acute testing not needed if ECG and high-sensitivity troponin are negative

20-HVI-1987645-scott-cameron-md-phd_650x450
November 6, 2020
New Head of Vascular Medicine Looks to Enhance Collaborative Caregiving

Scott Cameron, MD, PhD, also brings wide-ranging research interests to bear

20-HVI-1961368_Matthew-Thompson_650x450
September 30, 2020
Dr. Matthew Thompson Brings a Distinctly International Perspective to Endovascular Interventions

Pioneering U.K. vascular surgeon joins Cleveland Clinic

20-HVI-1961369-acute-stroke-in-brain_650x450
September 24, 2020
Stroke Risk in Cardiac Surgery: New Guidance for Averting a Dreaded Complication

AHA statement is first comprehensive document on perioperative stroke reduction

20-HVI-1896881 vascular-surgery-650×450
July 17, 2020
Cleveland Clinic Earns 3 Stars in Vascular Quality Initiative Registry Participation Program

Recognition reflects prioritization of long-term patient outcomes

20-HVI-1898975 Singh_Guidelines on CV imaging in athletes_CQD_650x450_993744768
June 15, 2020
First Formal Guidance Issued on Multimodality Cardiac Imaging in Young Athletes

Recommendations help distinguish exercise-induced remodeling from pathology

20-HVI-1894191-Primary-prevention-of-CVD-in-women
May 29, 2020
Guideline Update on Primary Cardiovascular Prevention in Women Takes on Conventional and Sex-Specific Risks

JACC review highlights factors unique to women, ways to tailor management

20-HVI-1892867-ablation-roundup-650×450
May 12, 2020
Trio of Studies at Virtual HRS Meeting Showcase Catheter Ablation Advances

Pushing the envelope in ablation of atrial fibrillation, ventricular tachycardia

Ad